PTHS (Channel) רווח נקי למניה (EPS TTM)

Channel Therapeutics (PTHS) relies on external contractors for testing, minimizing its own physical assets and adhering to basic environmental standards in laboratories. This chart on the GURU.Markets platform reflects a price trend serving as an indicator where the EPS value is -25.00. Business prospects are based on the development of drugs for rare CNS pathologies and the probability of a merger with industry behemoths.

Channel Therapeutics' specialization in neurotherapy development and its reliance on partner payments render profit dynamics volatile. Analyzing the relative change in EPS YoY (ttm) allows for an assessment of net income per share growth rates over a rolling year, filtering out market noise and revealing the actual efficiency of investment capitalization, which is critical for evaluating the fundamental stability of the biopharmaceutical business.